Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending February 21, 2016
Type 1 von Willebrand Disease, Studying variations in von Willebrand factor
Occult Hemorrhage in Idiopathic Thrombocytopenic Purpura, Does it predict subsequent bleeding?
Radiotherapy in Primary Mediastinal B-cell Lymphoma, Evaluating its effect on overall survival
Cytogenetic Abnormalities in Acute Lymphoblastic Leukemia, Assessing their prognostic value
Mortality and Vascular Events in Chronic Myeloid Leukemia, Are tyrosine-kinase inhibitors a risk factor?
Must reads for theWeek ending February 14, 2016
High-risk Subgroups in Hodgkin Lymphoma, Assessing risk for race, ethnicity, and status
Nilotinib in Chronic Myeloid Leukemia in Chronic Phase, Comparing safety and efficacy with imatinib
Von Willebrand Factor in Menorrhagia, Reducing bleeding in women with von Willebrand disease
Biclonal Gammopathies in Myelomas, Assessing their effect on progression
Emergency Department Visits in Sickle Cell Disease, Searching for interventions to improve outcomes
Must reads for theWeek ending February 7, 2016
Platelet-type von Willebrand Disease, Newly published ISTH guidelines for diagnosis and reporting
FDA Approves Kyprolis, Indicated for relapsed or refractory multiple myeloma
Incidence and Survival in Peripheral T-cell Lymphoma, Studying racial patterns of variation
Donor Leukocyte Infusion in Relapsed Leukemia and MDS, Comparing unrelated DLI with matched sibling DLI
Opioid Use in Pregnant Women With Sickle Cell Disease, Assessing its effect on neonatal abstinence syndrome
Must reads for theWeek ending January 31, 2016
Minimal Residual Disease in AML, Assessing its prognostic value
Hydroxyurea Use in Sickle Cell Disease, Should it be used more widely?
CTX-1 in Multiple Myeloma, Assessing levels before and after treatment
Hypomethylating Agents in Secondary AML, Evaluating prognoses after progression from myeolodysplastic syndromes
Young Age and Lymph Node Positivity, Studying associations in rectal cancer
Must reads for theWeek ending January 24, 2016
Guidelines on Sickle Cell Disease, A summary of 2014 NIH expert panel recommendation
Ibrutinib in Mantle Cell Lymphoma, Evaluating outcomes after resistance
Cranial Radiotherapy in Acute Lymphoblastic Leukemia, Assessing its impact on relapse risk
Ponatinib Therapy in Chronic Myeloid Leukemia, Studying outcomes in patients with TKI resistance
High Dose Daunorubicin in Acute Myeloid Leukemia, Studying possible benefits